A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome

Paolo G Arduino, Adriana Cafaro, Marco Garrone, Alessio Gambino, Marco Cabras, Ercole Romagnoli, Roberto Broccoletti, Paolo G Arduino, Adriana Cafaro, Marco Garrone, Alessio Gambino, Marco Cabras, Ercole Romagnoli, Roberto Broccoletti

Abstract

Comparison between low-level laser therapy (LLLT) and clonazepam for treating burning mouth syndrome (BMS) patients has never been documented; the aim of this study was to assess the effects of LLLT photobiomodulation versus medical therapy with clonazepam on BMS. Thirty-three patients (25 female, 8 male, mean age = 67.12) were randomly allocated to two different groups: the first one (group A, 18 patients) underwent two laser irradiation sessions weekly for 5 weeks, whereas the second one (group B, 15 patients) received topical clonazepam therapy [half a tablet (2 mg) in the mouth without swallowing for 3 min, three times a day for 21 days]. LLLT was delivered with a continuous wave 980-nm aluminum gallium arsenide (AlGaAs) diode laser and the output of 300 mW, delivering a Fluence of 10 J/cm(2), using a "spot technique," with an average power density of about 1 W/cm(2). The laser probe was held perpendicularly at a distance of about 2 mm from the mucosa. Visual analogue scale (VAS), McGill Pain Questionnaire, present pain intensity (PPI), and Oral Health Impact Profile (OHIP-49) assessed sensation of pain. Hospital Anxiety and Depression Scale and Geriatric Depression Scale assessed levels of anxiety and depression. Twelve weeks after the end of treatment, patients treated with LLLT experienced a decrease in pain sensation reported for all the parameters analyzed: VAS (P = 0.004), McGill Pain Questionnaire (P = 0.002), PPI (P = 0.002), and OHIP-49 (P = 0.010). The group treated with clonazepam had less favorable results for VAS (P = 0.33), McGill Pain Questionnaire (P = 0.005), PPI (P = 0.013), and OHIP-49 (P = 0.25). Levels of anxiety and depression did not change statistically in any groups (P > 0.05). Comparing the two groups, LLLT appeared to be superior in improving pain perception, but statistically only at 8 weeks after the end of the protocol proposed (P = 0.026). Based on this preliminary trial, LLLT is capable of reducing the symptoms of patients with BMS with a constant and long-lasting effect, experienced since the end of the first applications.

Keywords: BMS; Clonazepam; Low-level laser therapy; Randomized.

References

    1. Lasers Med Sci. 2009 Jan;24(1):113-6
    1. Pain. 2004 Mar;108(1-2):51-7
    1. Photomed Laser Surg. 2011 Dec;29(12):793-6
    1. J Oral Pathol Med. 2012 Apr;41(4):281-7
    1. J Oral Rehabil. 2005 Nov;32(11):800-7
    1. Ann Stomatol (Roma). 2010 Jan;1(1):14-8
    1. Ann Rheum Dis. 2002 Jun;61(6):554-8
    1. Br Dent J. 2007 Feb 10;202(3):131-8
    1. J Orofac Pain. 2011 Spring;25(2):125-30
    1. BMC Oral Health. 2015 Oct 23;15(1):131
    1. Lasers Med Sci. 2013 Jan;28(1):297-301
    1. Psychosom Med. 1998 May-Jun;60(3):378-85
    1. Int Arch Otorhinolaryngol. 2015 Jan;19(1):86-9
    1. Photomed Laser Surg. 2015 Apr;33(4):193-9
    1. Headache. 2012 Jun;52(6):1019-25
    1. Oral Dis. 2010 Nov;16(8):807-11
    1. J Biomed Opt. 2015 Sep;20(9):098001
    1. Int J Geriatr Psychiatry. 1999 Oct;14(10):858-65
    1. Int J Oral Maxillofac Surg. 2014 Jul;43(7):868-73
    1. Oral Dis. 2010 Oct;16(7):643-7
    1. J Psychosom Res. 2002 Feb;52(2):69-77
    1. J Oral Pathol Med. 2013 Oct;42(9):649-55
    1. Med Oral Patol Oral Cir Bucal. 2008 Oct 01;13(10):E648-52
    1. J Midlife Health. 2012 Jan;3(1):36-9
    1. Lasers Med Sci. 2014 Mar;29(2):559-64
    1. Photomed Laser Surg. 2010 Dec;28(6):835-9
    1. Rev Neurol. 2015 May 16;60(10):457-63
    1. Bull Group Int Rech Sci Stomatol Odontol. 2010 May 21;49(1):19-29
    1. Photomed Laser Surg. 2011 Feb;29(2):123-5

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner